RxDoctor Payments Data

Eric Starr, PA

Physician Assistant · Huntersville, NCNPI 1174625024

Payments from drug & device makers

$614in general payments, 2019–2025

Across 21 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180
  • Boehringer Ingelheim$111
  • Novo Nordisk$87
  • Pfizer$63
  • AbbVie$42
  • Lilly USA, LLC$30
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$59497%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$180
Boehringer Ingelheim1$111
Novo Nordisk4$87
Pfizer3$63
AbbVie2$42
Lilly USA, LLC2$30
Johnson & Johnson(2 entities)2$28
Bayer1$20
Organon1$18
Amgen1$17
GSK1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$614 in reported general payments places this provider in the 60th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,813
Medicare patients
103
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$9,895
Novolog FlexpenInsulin Aspart11$2,822
Gabapentin62$1,649
Methylphenidate ErMethylphenidate Hcl12$1,163
Ventolin HfaAlbuterol Sulfate16$926
Pregabalin19$910
Pantoprazole Sodium72$795
Albuterol Sulfate HfaAlbuterol Sulfate38$762
Metoprolol Succinate62$686
Omeprazole64$685
Atorvastatin Calcium105$637
Venlafaxine Hcl ErVenlafaxine Hcl17$605
Bupropion XlBupropion Hcl24$593
Fluticasone Propionate51$532
Levothyroxine Sodium75$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$9,89513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →